Overview

Memantine-enhanced Buprenorphine Treatment for Opioid-dependent Young Adults

Status:
Completed
Trial end date:
2013-10-01
Target enrollment:
0
Participant gender:
All
Summary
The purpose of this study is to examine the effect of memantine and buprenorphine on opioid abusing behavior, to determine the effect of memantine and buprenorphine on early relapse and to evaluate the tolerability of memantine co-administrated with buprenorphine. The study seeks to determine if combined treatment of memantine and buprenorphine may provide shorter-term treatment for opioid dependence.
Phase:
Phase 2/Phase 3
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
University of Massachusetts, Worcester
Collaborator:
National Institute on Drug Abuse (NIDA)
Treatments:
Buprenorphine
Memantine
Criteria
Inclusion Criteria:

- Men and women between 18-25 years old

- Opioid dependence as evidenced by signs of opiate withdrawal, self-reported history of
opioid dependence for a consecutive 12 month period and positive urine for opioids

Exclusion Criteria:

- Current diagnosis of other drug or alcohol dependence (other than opiates, cannabis or
tobacco)

- Serious medical illness (e.g. major cardiovascular, renal, endocrine, hepatic
disorder)

- Current serious psychiatric illness or history of psychosis, schizophrenia, bipolar
type I disorder and participants with suicidal or homicidal thoughts

- Women who are pregnant, nursing or refuse to use a reliable form of birth control or
refuse monthly pregnancy testing

- Screening liver function tests (SGOT or SGPT) greater than 3 times normal